Cart
sales@molnova.com
Home - Products - Apoptosis - IL Receptor - Risankizumab

Risankizumab

CAS No. 1612838-76-2

Risankizumab( —— )

Catalog No. M36713 CAS No. 1612838-76-2

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 369 Get Quote
5MG 753 Get Quote
10MG 1169 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Risankizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.
  • Description
    Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
  • In Vitro
    Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds <10 pM.Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively.
  • In Vivo
    Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days) Dosage:1 mg/kg Administration:i.p.; single dosage Result:Significantly inhibited IL23-induced ear swelling and cytokine production.Animal Model:Cynomolgus monkeys Dosage:1.0 mg/kg Administration:i.v. or s.c.Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1612838-76-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019 Jun;79(8):893-900.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Deoxyandrographolide

    Deoxyandrographolide potentiates NGF-induced neurite outgrowth. Deoxyandrographolide suppresses the production of proinflammatory mediators TNF-α and IL-6.

  • MyD88-IN-1

    MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.

  • Nodosin

    Nodosin has an anti-inflammatory function via inhibition of IL-2. Nodosin perfusion provides a potential protective effect by inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation.

Sign In Join Free